GCC Syringes and Needles Market Reaches USD 762 Mn in 2026, Driven by Expanding Healthcare Infrastructure and Rising Demand for Injectable Therapies

Technological Innovations and Increasing Adoption of Safety-Engineered Devices to Drive GCC Syringes and Needles Market to USD 1,087 Mn by 2033 at 5.2% CAGR – Coherent Market Insights

GCC Syringes and Needles Market, by Product Type (Oral and Hypodermic {Standard and Special Purpose [Insulin, Tuberculin, Angiographic, and Others]), by Usability (Disposable and Reusable), by Material (Glass and Polymer), by End User (Hospitals, Blood Collection Centers, Diabetic Care Center, Veterinary Care Center, and Others), and by Country (Kingdom of Saudi Arabia,  U.A.E.,  Qatar,  Bahrain,  Oman, and Kuwait) is estimated to be valued at US$ 252.3 Million in 2022 and is expected to exhibit a CAGR of 9.1% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Increased prevalence of chronic diseases such as diabetes, cancer, cardiovascular diseases, and others in the region is expected to drive the market growth in the region over the forecast period. For instance, according to the data provided by the National Center for Biotechnology Information, in July 2022, breast cancer is the most commonly diagnosed cancer, accounting for 2.3 million new cases annually which makes up 11.7% of total new cancer cases in 2020, in United Arab Emirates (UAE)

Market Drivers

Rising investment in vaccination, injectable therapies, clinical research, and healthcare infrastructure is a major driver of the GCC syringes and needles market. Syringes and needles are extensively consumed in vaccine administration, insulin delivery, blood collection, diagnostic procedures, and hospital-based drug delivery. For instance, in June 2026, the Department of Health–Abu Dhabi and Sanofi announced plans to develop a Vaccine Innovation Centre covering mRNA research, clinical development, vaccine manufacturing, and expanded access to advanced vaccines. This development is expected to increase demand for sterile disposable syringes, hypodermic needles, and safety-engineered injection devices across the GCC. (Source: Department of Health)

Market Opportunity

The rapid expansion of hospitals, specialized clinics, day-surgery centers, and home healthcare services across GCC countries creates significant opportunities for syringe and needle manufacturers. Growing healthcare capacity will generate recurring demand for disposable syringes, safety-engineered needles, insulin syringes, pen needles, and blood-collection products. Companies can capitalize on this opportunity through local manufacturing, regional warehousing, government procurement partnerships, and long-term supply agreements with private healthcare providers.

For instance, in February 2026, the Government of Dubai Media Office reported that Dubai’s licensed healthcare facilities increased by more than 8% to approximately 5,800 in 2025. These included 55 hospitals, 68 specialized clinics, 60 day-surgery centers, and 222 home healthcare centers, indicating an expanding institutional and home-care customer base for injection consumables. (Source: investsaudi.sa)

Market Trends

• Increasing Localization of Medical-Product Manufacturing

Governments are prioritizing local pharmaceutical and medical-product manufacturing to reduce import dependence and strengthen supply security. This trend can create opportunities for regional production and procurement of disposable syringes, needles, and related injection components. For instance, in May 2026, the Emirates Drug Establishment and Arcera Life Sciences signed an agreement to expand UAE manufacturing capacity and strengthen strategic stockpiles of medical products.

• Expansion of Vaccine Research and Clinical Manufacturing

GCC countries are strengthening vaccine research, clinical development, and local manufacturing capabilities, which is expected to increase the requirement for sterile syringes, hypodermic needles, and ready-to-use injection systems. For instance, in June 2026, the Department of Health–Abu Dhabi and Sanofi announced plans to explore a Vaccine Innovation Centre in Abu Dhabi covering mRNA research, clinical development, advanced manufacturing, and vaccine commercialization.

• Digitalization of Vaccination Access and Records

Digital health platforms are making vaccination appointments and immunization records more accessible, supporting higher utilization of preventive healthcare services and more efficient syringe and needle inventory planning. For instance, Saudi Arabia’s Ministry of Health updated its Sehhaty platform in June 2026, providing vaccination appointment booking, children’s vaccination records, digital health wallets, and other preventive healthcare services.

• Shift Toward Advanced and Automated Insulin Delivery

Diabetes care in the GCC is increasingly moving from conventional insulin syringes toward wearable, automated, and digitally connected delivery systems. This transition is reshaping demand toward specialized cannulas, infusion components, pen needles, and disposable drug-delivery consumables. For instance, in February 2026, Insulet launched the Omnipod 5 automated insulin-delivery system in Saudi Arabia, Kuwait, Qatar, and the UAE, reducing the need for multiple daily injections.

• Greater Focus on Diabetes Management and Injection-Related Care

The high burden of diabetes across GCC countries continues to support demand for insulin syringes, pen needles, blood-sampling needles, and other diabetes-management consumables. For instance, in March 2026, Saudi Arabia’s Ministry of Health reported that the Saudi Red Crescent had responded to 2,042 diabetes-related emergency cases since the beginning of Ramadan, highlighting the continuing need for effective diabetes monitoring and treatment.

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/gcc-syringes-and-needles-market-3472

Key Takeaways of the GCC Syringes and Needles Market

• The GCC syringes and needles market is expected to grow during the forecast period, supported by government initiatives aimed at improving diabetes awareness, prevention, screening, and disease management. For instance, in February 2026, Qatar’s Ministry of Public Health organized community health-awareness activities covering diabetes and obesity prevention, tobacco control, first-aid training, and blood donation as part of National Sport Day. Such initiatives can encourage early diagnosis and diabetes management, supporting demand for insulin-delivery syringes and needles.
• Among product types, hypodermic segment is expected to dominate the segment growth over the forecast period, owing to the increasing approvals for prefilled syringes by the regulatory bodies to the key players. For instance, in January 2022, GSK plc., a multinational pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved a 40 mg prefilled syringe of Nucala (mepolizumab) for children aged 6 to 11 years old suffering from eosinophilic asthma (SEA).
• Among countries, Kingdom of Saudi Arabia is estimated to account for the largest market share in the GCC syringes and needles market over the forecast period, owing to the increasing partnerships between key players in the country to increase the manufacturing syringes. For instance, in December 2021, Saudi Chemical Company Holding, an investment company, through its pharmaceutical sector represented by AJA Pharma, providing a wide range of pharmaceutical products in various finished dosage forms for different therapeutic classes, and Sanofi, a multinational healthcare company, signed a memorandum of understanding (MOU) to explore the possibility of manufacturing Sanofi’s Clexane prefilled syringes in the Kingdom of Saudi Arabia.
• Major players operating in the GCC syringes and needles market include Becton, Dickinson and Company, Nipro Corporation, Baxter International Inc., B. Braun Melsungen AG, Terumo Corporation, Medtronic plc., Smiths Group plc., Abu Dhabi Medical Devices Company, IBN Sina Medical Factory, Alshifa Medical Syringes Manufacturing Company Limited, International Korean Medical Company, Mais Saudia, and VITREX Medical A/S

Key Developments

• In February 2026, Healthium Medtech, a global, precision-focused medical technology company showcased its comprehensive specialty needle portfolio at World Health Expo Dubai, held at the Dubai Exhibition Centre in the UAE. The portfolio was presented as being engineered to provide improved precision, procedural control, and consistency across multiple surgical applications. The regional showcase introduced GCC healthcare providers, distributors, and procurement teams to advanced needle designs, supporting the adoption of higher-quality and procedure-specific medical consumables.
• In January 2026, West Pharmaceutical Services announced the commercial availability of its Synchrony S1 Prefillable Syringe System. The integrated platform combines the syringe barrel, plunger, and needle-shield or tip-cap components within one verified system. The innovation can support pharmaceutical companies supplying GCC markets by simplifying component selection, reducing drug-device compatibility risks, and accelerating the development of injectable biologics and other prefilled therapies. (Source: West Pharmaceutical Services)